Description

Opsta‑D is a fixed‑dose ophthalmic solution combining a fluoroquinolone antibiotic (levofloxacin) with a corticosteroid (dexamethasone). It’s designed to prevent and treat inflammation and prevent bacterial infection, commonly associated with cataract surgery or other ocular procedures 

2. Prescription

Prescription-only product (POM/Rx). A doctor’s authorization is required 

3. Therapeutic Category

Belongs to the class corticosteroid + anti‑infective combination, used for anti-inflammatory and antibacterial ophthalmic purposes, typically post-operative ocular care.

4. Active Ingredients / Composition

• Levofloxacin Hemihydrate (antibacterial): typically 5 mg/mL (0.5%)
• Dexamethasone Sodium Phosphate (anti‑inflammatory corticosteroid): typically 1 mg/mL (0.1%)
• Preservative: Benzalkonium Chloride (e.g. 0.005%) .

5. Vitamins

None included.

6. Minerals

None included.

7. Variant

Usually available in standard 0.1% dexamethasone + 0.5% levofloxacin formulation. Packaged volumes commonly include 5 mL bottles.

8. Consume Type

Ophthalmic solution (eye drops) for topical use on the eye. Not for internal use.

9. Directions / Usage

• Typical dosing (adults, post-surgery): Instill one drop into the conjunctival sac every 6 hours (i.e., 4 times daily) for 7 days .
• Alternate regimen (when more intensive initial control needed):
  • Days 1–2: 1–2 drops every 2 hours, up to 8 times/day
  • Days 3–7: 1–2 drops every 4 hours, up to 4 times/day.
• Treatment should not be stopped prematurely; taper if advised.
• Avoid contact with dropper tip; maintain sterility. Press on the tear duct (nasal corner) post-application to reduce systemic absorption 

10. Common Side Effects

• Eye-related: irritation, ocular hypertension, sensation of a foreign body, blurred vision, corneal edema, increased tearing, discomfort, and dryness.
  Systemic / less common: headache, dysgeusia (taste changes) 
• Risks from corticosteroid use: elevated intraocular pressure, risk of glaucoma, formation of subcapsular cataracts (especially in diabetics), and possible corneal thinning or perforation 

11. Package Type

Typically supplied in a 5 mL LDPE (low-density polyethylene) dropper bottle, sometimes also in 3 mL or 10 mL sizes depending on brand/manufacturer.

12. Storage Advice

• Store at room temperature, generally below 25–30 °C, away from light and moisture.
• Discard 28 days (4 weeks) after opening.
• Keep out of reach of children, avoid freezing
  

13. Safety Advice

• Ophthalmic use only.
• Avoid contamination: do not touch dropper tip to eye/skin. Keep cap tightly closed.
• Monitor intraocular pressure if using for extended periods.
• Contraindications: known hypersensitivity to levofloxacin or dexamethasone, steroid-responsive infections (e.g., viral, fungal, mycobacterial eye infections) .
• Avoid use in children/adolescents (typically <18 years) due to lack of safety data .
• Pregnancy & lactation: Use only if benefits outweigh risks. Data limited .
• Long-term steroid use risks: glaucoma, cataracts, slowed corneal healing.
• Discontinue if signs of secondary infection or corneal damage appear.

14. Product Substitute

Therapeutically similar products include:

• Ducressa (levofloxacin + dexamethasone) by Santen/Tubilux .
  Dexalev (levofloxacin 0.5% + dexamethasone 0.1%) by Aristovision, approved in EU/UK, offering a 7-day regimen.
• Levodexa (combo product approved in Canada, brand name).

15. Manufacturer / Marketer

Likely manufacturer: Ha Noi CPC1 Pharmaceutical JSC (CPC1, Vietnam), as they produce “Dexalevo Drop” — a levofloxacin/dexamethasone product similar to Opsta‑D.
Other manufacturers include:

• Tubilux Pharma S.p.A., distributed by Santen (e.g., Ducressa) .
  Aristovision (Dexalev).

16. Country of Origin

Depending on manufacturer:

• Vietnam (CPC1) for Dexalevo-like products.
• Italy (Tubilux Pharma) for Ducressa; distributed in Malaysia & others 
• Europe (Spain origin of raw materials) for Dexalev